India’s AI eye tech gets a global boost as investors bet big on vision’s digital future.
Inviga Healthcare Fund (IHF; Bengaluru, India) has acquired a 21% stake in Forus Health (Bengaluru, India), signaling strong investor confidence in India’s capability to produce scalable, AI-powered ophthalmic technologies for global use. The deal emphasizes IHF’s focus on healthcare ventures that combine clinical expertise with innovation, particularly in the field of preventive diagnostics.
Forus Health continuing impact
Forus Health’s claim to diagnostic fame is its affordable 3nethra series of screening devices, which are now used in more than 75 countries, reaching over 22 million patients. Its recent innovation, the 3nethra specto, is the world’s first wearable digital refractor controlled through a smartphone, opening new possibilities for remote and tele-optometry applications.
The company’s integrated digital eye-health platform—supported by artificial intelligence for ocular and oculomics applications—has made early disease detection more accessible, especially in resource-limited settings.
READ MORE: AI-Powered Handheld Fundus Imaging: How Optomed’s Aurora AEYE Empowers Optometrists
In recognition of its contribution to accessible vision care, TIME Magazine named Forus Health among the “World’s Top 400 HealthTech Companies in 2025,” highlighting its influence in bridging technology and clinical need.
Supporting India’s medtech in eye health
This investment marks Inviga’s second major healthcare acquisition after its 2024 support of vaccine developer Mynvax (Bengaluru, India). The fund focuses on advancing sustainable and outcome-based healthcare systems built on location innovation.
READ MORE: AI in Ophthalmology: Maximizing Potential while Ensuring Data Safety
Tackling preventive blindness
Conditions like diabetic retinopathy (DR) and retinopathy of prematurity (ROP) remain an important challenge in both developing and developed healthcare systems worldwide.
READ MORE: The Retina’s Early Warnings
Globally, over 2.2 billion people are affected by vision impairment or blindness, with more than 1 billion cases considered preventable or treatable.* It emphasizes the ongoing need for scalable, affordable diagnostic solutions—the very space Forus Health continues to pioneer.
Looking ahead
With Inviga’s backing, Forus Health is poised to expand its footprint and accelerate the adoption of connected, AI-based diagnostic systems worldwide. For ophthalmologists, this development reflects a wider movement toward data-driven, early-stage screening that can help reduce the long-term burden of eye disease.
*Blindness and vision impairment. World Health Organization. August 10, 2023. Available at: https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment. Accessed on November 4, 2025. .
Editor’s Note: This content is intended exclusively for healthcare professionals. It is not intended for the general public. Products or therapies discussed may not be registered or approved in all jurisdictions, including Singapore.